FOLFIRI-Aflibercept combination a new light of hope for Colorectal cancer patients following a failed oxaliplatin-based chemotherapy

Colorectal cancer (CRC) is the third most common invasive tumor, and one of few cancers to show a progressive and steady increase worldwide, with more than 1.5 million cases registered annually, basic risk factors include changes in the dietary pattern and adaptation of western lifestyles in eastern countries. [1][4][6]

According to the WHO the incidence of CRC is peaking in many Asian countries, which can be attributed to the adaptation of unhealthy lifestyles, and while the mortality to incidence ratio is increasing in some countries, indicating a poor prognosis and a lower survival rate, the median survival rate of patients with CRC is notably increasing, showing significant improvements in the healthcare domain, which can be attributed to the technical evolution and workflow dedication of healthcare professionals and scientists, the introduction of novel chemotherapeutic combinations, paved a light of hope for many critically ill patients in the terminal stage of CRC, especially for those following a failed oxaliplatin chemotherapy. A retrospective analysis of 19 CRC Asian patients was held in the period between April 2012 and December 2013 to evaluate the adverse effects and safety of standard chemotherapy combination in patients suffering of progressive metastatic colorectal cancer,  results obtained following a median follow-up duration of 9.6 months were astonishing, as fifth of the patients achieved a partial response, and half of the patients achieved a stable disease with a disease control rate of 63.2%, whereas no therapeutic related deaths were reported. [5][7][8]

The clinical benefits of administering FOLFIRI/aflibercept combination in patients with progressive metastatic colorectal cancer is undoubted, results obtained confirmed the usage safety of this drug combination and proved that it is an option treatment to give hope for critically ill patients following a failed oxaliplatin based therapy.

 

 

 

References

1. Seow A, Quah SR, Nyam D, Straughan PT, Chua T, Aw TC. Food groups and the risk of colorectal carcinoma in an Asian population. Cancer 2002; 95: 2390–96.
2. Treatment of Colon Cancer by Stage. American Cancer Society Web site 2015 February 27. [Cited 4 April 2015.] Available from URL: http://www.cancer.org/cancer/ colonandrectumcancer/detailedguide/colorectal-cancertreating- by-stage-colon
3. Libutti SK, Saltz SB, Willett CG. Cancer of the colon. In: Devita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles& Practice ofOncology. 9th edn. LippincottWilliams and Wilkins, Philadelphia, PA 2011; 1084–126
4. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: Implications for screening.Lancet Oncol 2005; 6: 871–76.
5. Epidemiology and burden of colorectal cancer in Asia-Pacific region: What shall we do now? Transl Gastrointest Cancer 2014; 3: 169–73.
6. Colorectal cancer statistics. World Cancer Research Fund International Fund Web site. [Cited 18 Sept 2015.] Available from URL: http://www.wcrf.org/int/cancer-factsfigures/ data-specific-cancers/colorectal-cancer-statistics
7. Colorectal Cancer. Health Promotion Board Singapore Web site 2014 October 23. [Cited 4 Sept 2015.] Available from URL: http://www.hpb.gov.sg/HOPPortal/dandcarticle/598.
8. Cancer Screening. National University Cancer Institute, Singapore 2012. [Cited 4 Sept 2015.] Available from URL: http://www.ncis.com.sg/cancer-information/cancerscreening.html.

Verified by: Dr.Diab (January 7, 2017)

Citation: Dr.Diab. (January 7, 2017). FOLFIRI-Aflibercept combination for Colorectal cancer. Medcoi Journal of Medicine, 4(2). urn:medcoi:article16563.